A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Phase 2 – studying effectiveness and dosage
Conditions:
Homeostatic iron regulator gene-related hereditary hemochromatosis
Sponsor: CSL Behring LLC
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC) ,
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 25 participants
БГ